<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216267</url>
  </required_header>
  <id_info>
    <org_study_id>HSREB16279</org_study_id>
    <nct_id>NCT01216267</nct_id>
  </id_info>
  <brief_title>Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples</brief_title>
  <official_title>Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Western Ontario, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to compare several methods for measurement of Chromogranin A in
      their ability to serve as a marker for disease activity in patients with neuroendocrine
      tumors.

      Further, in a subgroup, we will determine if taking a proton pump inhibitor affects
      Chromogranin A levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chromogranin A concentration serum</measure>
    <time_frame>single time</time_frame>
    <description>For determination of normal CgA range, we will recruit 60 healthy subjects (30 female, 30 male), in whom a single plasma sample will be obtained for measurement of CgA B For determination of CgA in patients with carcinoid disease (active or inactaive), we wil recruit 200 patients with carcinoid disease from our local neuroendocinre oncology clinic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of PPI on chromogranin A concentration</measure>
    <time_frame>2 weeks</time_frame>
    <description>To determine the effect of PPI on chromogranin A concentration, we will recruit a subgroup of 12 healthy subjects who will take a bedtime lansoprazole 30 mg for 7 days. Fasting serum samples for CgA will be obtained at day 7 and 1, 2, 4, and 7 days after discontinuation of the PPI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Neuroendocrine Carcinoma (Carcinoid)</condition>
  <arm_group>
    <arm_group_label>lansoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lansoprazole for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>lansoprazole 30 mg HS x 7 days</description>
    <arm_group_label>lansoprazole</arm_group_label>
    <other_name>Prevacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lansoprazole</intervention_name>
    <description>lanzoprazole 30 mg HS for 7 days</description>
    <arm_group_label>lansoprazole</arm_group_label>
    <other_name>pravacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients:

        Inclusion Criteria:

          -  having neuro-endocrine disease

        Exclusion Criteria:

          -  age below 18 or above 70 years

          -  prostate cancer

          -  kidney failure (estimated GF &lt; 30 mL/Min)

          -  heart failure

          -  chronic atrophic gastritis

          -  pregnancy

        Healthy subjects:

        Inclusion Criteria:

          -  healthy

        Exclusion Criteria:

          -  age below 18 or above 70 years

          -  taking any chronic medication (except OCP)

          -  prostate cancer

          -  kidney failure (estimated GFR &lt; 30 mL/min)

          -  heart failure

          -  pheochromocytoma

          -  islet cell tumors

          -  medullary thyroid cancer

          -  essential hypertension

          -  neurofibromatosis

          -  use of proton pump inhibitors

          -  chronic atrophic gastritis

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stan Van Uum, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Center and St. Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Western Ontario, Canada</investigator_affiliation>
    <investigator_full_name>Stanislaus H. van Uum</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>chromogranin A</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>carcinoid</keyword>
  <keyword>Proton Pump Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

